Cutaneous Mastocytosis Treatment Market
Cutaneous Mastocytosis Treatment Market Study by Antihistamines, Steroids, Mast Cell Stabilizers, Adrenergic Agonists, Psoralens (Methoxsalen), and Others from 2024 to 2034
Analysis of Cutaneous Mastocytosis Treatment Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Cutaneous Mastocytosis Treatment Market Outlook (2024 to 2034)
The global cutaneous mastocytosis treatment market size is estimated to be US$ 290.3 million in 2024, and is expected to reach at US$ 402.9 million by 2034, with a projected compound annual growth rate (CAGR) of 3.3% during the forecast period from 2024 to 2034.
Salient Trends Backing the Demand for Cutaneous Mastocytosis Treatment
- Despite no permanent solution for cutaneous mastocytosis yet discovered, photochemotherapy is emerging as an effective combination of long-wave UV radiation and drug psoralens to treat this issue. This therapy has been showing positive outcomes and is now increasingly being utilized as a treatment choice for cutaneous mastocytosis.
- Spreading knowledge about cutaneous mastocytosis by NGOs and government entities is expected to boost market expansion over the forecast period. Knowledge about this disease and related treatment and diagnosis is increasing the understanding of symptoms and treatment among infants’ parents to seek immediate medical attention at the slightest hint of the disease.
- Surging investments in progressive activities like research and drug development by leading players are strengthening the discovery process to find effective treatment options. Various novel prognostic and diagnostic factors are being focused on making therapy more effective and managable. Further, the ongoing progress in pathogenesis is projected to create new prospects for better disease management, thus increasing market growth.
| Report Attributes | Details |
|---|---|
| Estimated Market Value (2024E) | US$ 290.3 million |
| Forecasted Market Value (2034F) | US$ 402.9 million |
| Global Market Growth Rate (2024 to 2034) | 3.3%CAGR |
| Antihistamines Segment Growth Rate (2024 to 2034) | 3.1% CAGR |
| Oral Segment Growth Rate (2024 to 2034) | 3.7% CAGR |
| North America Market Share (2024) | 40.7% |
| Latin America Market Share (2024) | 4% |
| Key Companies Profiled in the Cutaneous Mastocytosis Treatment Market Report |
|
Don't Need a Global Report?
save 40%! on Country & Region specific reports
What Emerging Opportunity is Favoring Market Expansion?
“Numerous Treatment Options for Cutaneous Mastocytosis”
Plethora of treatments like proton pump inhibitors, antihistamines, steroids, epinephrine, and tyrosine kinase inhibitors are the top preferences to treat and relieve various symptoms of systemic mastocytosis. These are progressively being prescribed to patients inflicted by systemic mastocytosis to enhance their quality of life.
Which Factors Restrain the Cutaneous Mastocytosis Market Growth?
“Unaffordable Price Range of Treatment Procedures”
The treatment and medications required to relieve symptoms of cutaneous mastocytosis are on the higher end, cost-wise. Despite photochemotherapy success among the masses as an effective treatment for cutaneous mastocytosis, patients in underdeveloped countries find it unaffordable. Therefore, the high price of therapy and medication is creating obstacles to market growth.
“Severe Side Effects Associated with Photochemotherapy”
People undergoing photochemotherapy run the chances of experiencing side effects like itching, burning, tanning, nausea, etc. Additionally, pregnant women and people with psoriasis are also prohibited from undergoing this therapy. Thus restricting market growth.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Country-wise Insights
The North America cutaneous mastocytosis treatment market is anticipated to account for a share of 40.7% in 2024. The market share is projected to reach 41.2% by 2034, expanding at a CAGR of 3.4% through 2034. Latin America is estimated to hold a share of 4% in 2024. By 2034, it is forecasted to grow to 4.4%, registering a CAGR of 4.2% throughout the period.
Which Factors are Consolidating the United States Position on the Global Platform?
“Constant Efforts Toward New Breakthroughs as Well as Educational Campaigns for this Disease is Propelling Market”
The United States acquired a leading stance in the global arena, with a prominent market share. Regionally, its share is expected to be 85.3% in 2024. The market in the country is set to generate a value of US$ 101 million in 2024. By 2034, the market is projected to be worth US$ 140 million, expanding at a CAGR of 3.4%.
Increasing dissemination of knowledge by NGOs and government bodies has been instrumental in raising the diagnosis rate of cutaneous mastocytosis in the United States. Surging investments into research are helping develop new medications and therapies to improve efficacy and patients’ quality of life. Additionally, the establishment of a well-developed healthcare system is facilitating access to advanced diagnostics, specialists, and new treatment options.
Which Factors Support the Growth of the Market in Brazil?
“Increasing Education About Rare Skin Disorders and Expanding Healthcare Infrastructure are Propelling Brazil’s Market”
The Brazil cutaneous mastocytosis treatment market is expected to have a market share of 71.4% in Latin America. The market is set to be valued at US$ 8 million in 2024. By 2034, the market is set to reach US$ 13 million, expanding at a CAGR of 4.4% in the meanwhile.
The main market is projected to be pushed by expanding healthcare infrastructure in the country, which is raising the diagnosis rate. Increasing efforts to enhance infrastructural development such as educational institutes, transport, healthcare, etc., is favoring the market development in the country.
Segment-wise Insights
Based on drug class, the antihistamines segment is estimated to acquire a market share of 48.3% in 2024. Value-wise, the segment is projected to attain US$ 140.1 million in 2024. The market is estimated to reach US$ 190.5 by 2034, expanding at a CAGR of 3.1%. The mast cell follows behind the antihistamines segment and is estimated to acquire 25.6% in 2024.
The segment is forecast to be valued at US$ 74.2 million in 2024 and extrapolate to US$ 106.6 million by 2034. Meanwhile, the segment is projected to record a steady CAGR of 3.7%.
By route of administration, the oral segment is anticipated to acquire 80% market share in 2024. Based on value, the segment is expected to obtain revenue worth US$ 232.2 million in 2024. By 2034, the segment is projected to be valued at US$ 332.6 million, expanding at a CAGR of 3.7%.
On the basis of indication, the maculopapular cutaneous mastocytosis segment is expected to acquire a market share of 72% in 2024. The segment’s value is projected to be US$ 209.1 million in 2024. By 2034, the segment’s value is expected to be US$ 270.3 million, expanding at a CAGR of 2.6%.
Based on the distribution channel, the retail pharmacies segment is anticipated to gain a 48.5% market share in 2024. The segment is projected to generate revenue worth US$ 140.8 million in 2024. By 2034, the segment is anticipated to be valued at US$ 195.2 million, expanding at a CAGR of 3.3%. Following behind is the hospital segment, which is anticipated to account for a market share of 36.9% in 2024. The segment is going to be worth US$ 107.2 million in 2024. By 2034, the segment’s value is projected to be US$ 138.7 million, registering a CAGR of 2.6%.
Why is the Oral Route of Administration Highly Preferred Among the Masses?
“Easy Compliance and Convenience of Oral Medications Increasing their Preferability Among Patient Population ”
The oral indication is prominent in the cutaneous mastocytosis treatment market. The segment is projected to be driven by its convenience and non-invasive method, as compared to infusions, injections, or topical creams. An increasing count of patients are opting for less intrusive treatment options, thus propelling this segment's growth. Additionally, due to its easy compliance, patients are more likely to stick to long-term treatment regimens. Thus potentially resulting in improved treatment options.
Which Distribution Channel Garners Significant Revenue?
“Retail Pharmacies Witness Substantial Sales”
Retail pharmacies are observing heightened sales of medications for the treatment of cutaneous mastocytosis. This distribution channel provides more convenience and access as opposed to specialty clinics or hospital pharmacies. They are usually situated in easy-to-access neighborhoods and are open till late in the night, making it convenient for patients to purchase medications. Retail pharmacies, with their emphasis on chronic disease management and prescription fulfillment, are well-equipped to provide regular refills and offer patients constant support and counsel. Thus increasing their preference among the masses.
Hospitals also acquire a massive market share, less than retail pharmacies. The segment is projected to obtain 36.9% in 2024. The segment is expected to generate sales worth US$ 107.2 million in 2024 and US$ 138.7 million by 2034, meanwhile recording a CAGR of 2.6%. Typically, the ready availability of prescribed medicines in a similar hospital where diagnoses took place is a key factor in raising market sales.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Competitive Landscape
Market leaders are financing research and development to generate novel treatment modalities. Players are also engulfing smaller companies to widen their offerings and gain the upper hand. Players are further targeting new markets where cutaneous mastocytosis is expanding, and market competition is also damp.
Industry participants are focusing on partnerships with pharmacies, hospitals, and healthcare providers to increase their patient reach and medication. Market contenders are further investing in awareness campaigns and awareness to educate patients and healthcare professionals about current treatment options.
Featuring Recent Developments in the Cutaneous Mastocytosis Treatment Market
- In December 2023, AYVAKYT of Blueprint Medicines gained approval from the European Commission as the only treatment drug for indolent systemic mastocytosis. The drug showed substantial improvements in a broad spectrum of symptoms with a safety profile similar to placebo.
- In January 2023, the FDA permitted a priority review to sNDA, short for supplemental new drug application to Avyakit to treat indolent systemic mastocytosis, as per the declaration from Blueprint Medicines Corporation.
Segmentation of Cutaneous Mastocytosis Treatment Market Research
-
By Drug Class:
- Antihistamines
- Steroids
- Mast Cell Stabilizers
- Adrenergic Agonists
- Psoralens (Methoxsalen)
- Others
-
By Route Of Administration:
- Oral
- Injectable
- Topical
- Others
-
By Indication:
- Maculopapular Cutaneous Mastocytosis
- Diffuse Cutaneous Mastocytosis
- Solitary Cutaneous Mastocytoma
-
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Drug Stores
- Online Pharmacies
-
By Region:
- North America
- Europe
- Latin America
- East Asia
- South Asia and Oceania
- The Middle East and Africa
- FAQs -
What was the Value of the Cutaneous Mastocytosis Treatment Market in 2019?
The global cutaneous mastocytosis treatment market was worth US$ 247.1 million in 2019.
What is the Sales Outlook for Cutaneous Mastocytosis Treatment in 2024?
The sales outlook for cutaneous mastocytosis treatment will likely be valued at US$ 290.3 million in 2024.
What is the Demand Forecast for Cutaneous Mastocytosis Treatment for the Decade?
Demand for cutaneous mastocytosis treatment is projected to reach a market value of US$ 402.9 million by the end of 2034.
What is the Adoption Growth Projection for the Cutaneous Mastocytosis Treatment Market?
Demand for cutaneous mastocytosis treatment will rise at a CAGR of 3.3% through 2034.
At What Rate Is the Market in North America Predicted to Grow?
The North America market for cutaneous mastocytosis treatment is forecast to expand at a CAGR of 3.4% through 2034.
Cutaneous Mastocytosis Treatment Market